^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Prostate Cancer
    Drug:onilcamotide (RV001) (Immunostimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    RhoVac Press Release
    Title:

    RhoVac’s Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

    Published date:
    11/25/2020
    Excerpt:
    FDA has granted Fast Track Designation to RhoVac’s drug candidate, RV001. The drug candidate is currently engaged in a phase IIb clinical trial in prostate cancer, a study that aims to recruit more than 175 patients and that involves centres both in Europe and in the US.